Last reviewed · How we verify
NCT05463276
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
trial in Breast Cancer in 690 participants. Completed in 1 May 2022.
1 May 2022
Quick facts
| Lead sponsor | Sindh Institute of Urology and Transplantation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 690 |
| Start date | 28 February 2022 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 May 2022 |
| Sites | 1 location across Pakistan |
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Breast Cancer Invasive — all drugs for Breast Cancer Invasive →
- Breast Cancer Stage — all drugs for Breast Cancer Stage →
Sponsor
Sindh Institute of Urology and Transplantation
Who can join
Adults 18 to 80, any sex, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This cross-sectional study, conducted at the Sindh Institute of Urology and Transplantation (SIUT), involved a retrospective data review of all the patients diagnosed with breast cancer from March 2017 to December 2021. The demographic characteristics, clinical presentation, stage of the disease, and histopathological characteristics were analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05463276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Sindh Institute of Urology and Transplantation trials
Trials by the same sponsor.
- NCT07510178 — Retrograde Intrarenal Surgery Versus Extracorporeal Shockwave Lithotripsy · NA · not yet recruiting
- NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
- NCT07493356 — Difficult Airway Prediction by Integrating STOP-BANG Criteria · recruiting
- NCT07510542 — Comparison of Stress Response Evoked by Conventional Versus Videolaryngoscope · NA · recruiting
- NCT07334548 — Post-Surgical Outcomes of Conventional vs 3-Point Mesh Fixation in Lichtenstein Repair: An RCT · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05463276 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sindh Institute of Urology and Transplantation
- Last refreshed: 21 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing